• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

国际直肠癌消退分级研究小组:常用消退分级系统的观察者间变异性。

International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems.

机构信息

Department of Cellular Pathology, John Radcliffe Hospital and University of Oxford, OX3 9DU Oxford, UK.

出版信息

Hum Pathol. 2012 Nov;43(11):1917-23. doi: 10.1016/j.humpath.2012.01.020. Epub 2012 May 8.

DOI:10.1016/j.humpath.2012.01.020
PMID:22575264
Abstract

The aim of this study was to ascertain the level of concordance among gastrointestinal pathologists for regression grading in rectal cancers treated with neoadjuvant chemoradiation. Seventeen gastrointestinal pathologists participated using the Mandard, Dworak, and modified rectal cancer regression grading systems to grade 10 representative slides that were selected from 10 cases of rectal cancer treated with long-course neoadjuvant chemoradiation. The slides were scanned with a whole-slide scanner generating dynamic digitized images. The results showed very little concordance across the 3 grading systems, with κ values of 0.28, 0.35, and 0.38 for the Mandard, Dworak, and modified rectal cancer regression grading systems, respectively. In only 1 of 10 study cases was there unanimous grading concordance using the modified rectal cancer regression grading system. It was felt that these systems lacked precision and clarity for reproducible, accurate regression grading. The study concluded that there was a need for a simple, reproducible regression grading system with clear criteria, a cumulative or composite score taking into account all sections of the tumor bed that is sampled rather than the worst section (highest grade), and there should be a uniform method of sampling of these specimens.

摘要

本研究旨在确定接受新辅助放化疗治疗的直肠癌患者的胃肠道病理学家在回归分级方面的一致性程度。17 位胃肠道病理学家使用 Mandard、Dworak 和改良直肠肿瘤消退分级系统,对 10 例接受长程新辅助放化疗的直肠癌患者的 10 个代表性切片进行分级。这些切片使用全切片扫描仪进行扫描,生成动态数字化图像。结果显示,这 3 种分级系统之间的一致性非常低,Mandard、Dworak 和改良直肠肿瘤消退分级系统的κ 值分别为 0.28、0.35 和 0.38。在 10 例研究病例中,只有 1 例使用改良直肠肿瘤消退分级系统进行了一致的分级。研究人员认为,这些系统缺乏精确性和清晰度,无法进行可重复、准确的回归分级。该研究得出结论,需要一种简单、可重复的回归分级系统,该系统应具有明确的标准,采用累积或综合评分,考虑到肿瘤床所有取样部位,而不仅仅是最差部位(最高等级),并且应该采用统一的方法对这些标本进行取样。

相似文献

1
International study group on rectal cancer regression grading: interobserver variability with commonly used regression grading systems.国际直肠癌消退分级研究小组:常用消退分级系统的观察者间变异性。
Hum Pathol. 2012 Nov;43(11):1917-23. doi: 10.1016/j.humpath.2012.01.020. Epub 2012 May 8.
2
Factors influencing reproducibility of tumour regression grading after high-dose chemoradiation of locally advanced rectal cancer.影响局部晚期直肠癌高剂量放化疗后肿瘤退缩分级可重复性的因素。
Histopathology. 2011 Jul;59(1):18-21. doi: 10.1111/j.1365-2559.2011.03888.x.
3
Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.新辅助放化疗后局部进展期直肠癌肿瘤退缩分级的基因表达谱。
Oncol Rep. 2012 Sep;28(3):855-61. doi: 10.3892/or.2012.1863. Epub 2012 Jun 14.
4
Assessment of tumor regression of esophageal adenocarcinomas after neoadjuvant chemotherapy: comparison of 2 commonly used scoring approaches.新辅助化疗后食管腺癌肿瘤退缩的评估:两种常用评分方法的比较。
Am J Surg Pathol. 2014 Nov;38(11):1551-6. doi: 10.1097/PAS.0000000000000255.
5
Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.新辅助治疗胰腺癌的回归分级:一项观察者间研究
J Clin Pathol. 2017 Mar;70(3):237-243. doi: 10.1136/jclinpath-2016-203947. Epub 2016 Sep 28.
6
Tumor regression in rectal cancer after intensified neoadjuvant chemoradiation: a morphometric and clinicopathological study.强化新辅助放化疗后直肠癌的肿瘤退缩:一项形态计量学和临床病理学研究
World J Surg Oncol. 2015 Apr 21;13:155. doi: 10.1186/s12957-015-0572-z.
7
Prognosis of rectal carcinoma after multimodal treatment: ypTNM classification and tumor regression grading are essential.直肠癌经多模式治疗后的预后:ypTNM 分类和肿瘤退缩分级至关重要。
Anticancer Res. 2013 Feb;33(2):559-66.
8
The prognostic value of grade of regression and oncocytic change in rectal adenocarcinoma treated with neo-adjuvant chemoradiotherapy.新辅助放化疗治疗直肠腺癌中肿瘤退缩分级和嗜酸细胞变的预后价值。
J Surg Oncol. 2012 Feb;105(2):130-4. doi: 10.1002/jso.22073. Epub 2011 Aug 12.
9
Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now.新辅助放化疗后肿瘤退缩的病理分级:临床需求迫在眉睫。
J Clin Pathol. 2012 Oct;65(10):867-71. doi: 10.1136/jclinpath-2012-200958. Epub 2012 Jun 25.
10
Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome.在食管及食管胃交界癌术前放化疗后对残留癌范围进行分级时,观察者间具有出色的一致性:这是患者预后的可靠预测指标。
Am J Surg Pathol. 2007 Jan;31(1):58-64. doi: 10.1097/01.pas.0000213312.36306.cc.

引用本文的文献

1
Predicting neoadjuvant chemoradiotherapy response in rectal cancer: Insights from biomarkers to clinical practice.预测直肠癌新辅助放化疗反应:从生物标志物到临床实践的见解
World J Gastrointest Surg. 2025 Jul 27;17(7):106724. doi: 10.4240/wjgs.v17.i7.106724.
2
Peritoneal regression grading score (PRGS): first evidence for independent predictive and prognostic significance.腹膜消退分级评分(PRGS):独立预测和预后意义的首个证据。
Pleura Peritoneum. 2023 May 18;8(2):55-63. doi: 10.1515/pp-2023-0014. eCollection 2023 Jun.
3
Rectal tumor fragmentation as a response pattern following chemoradiation.
直肠肿瘤碎片化作为放化疗后的一种反应模式。
J Gastrointest Oncol. 2022 Dec;13(6):2951-2962. doi: 10.21037/jgo-22-477.
4
Histopathological Growth Pattern in Colorectal Liver Metastasis and The Tumor Immune Microenvironment.结直肠癌肝转移的组织病理学生长模式与肿瘤免疫微环境
Cancers (Basel). 2022 Dec 28;15(1):181. doi: 10.3390/cancers15010181.
5
Peritoneal regression grading score (PRGS) in peritoneal metastasis: how many biopsies should be examined?腹膜转移中的腹膜消退分级评分(PRGS):应检查多少块活检组织?
Pleura Peritoneum. 2022 Sep 26;7(4):179-185. doi: 10.1515/pp-2022-0118. eCollection 2022 Dec.
6
H3K27me3 Immunohistochemical Loss Predicts Lower Response to Neo-Adjuvant Chemo-Radiotherapy in Rectal Carcinoma.H3K27me3免疫组化缺失预示直肠癌对新辅助放化疗的反应较低。
Biomedicines. 2022 Aug 21;10(8):2042. doi: 10.3390/biomedicines10082042.
7
MRI tumour regression grade in locally recurrent rectal cancer.局部复发性直肠癌的 MRI 肿瘤退缩分级。
BJS Open. 2022 May 2;6(3). doi: 10.1093/bjsopen/zrac033.
8
Tumor regression grade combined with lymph node status in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy.新辅助放化疗后食管鳞癌的肿瘤退缩分级与淋巴结状态。
Cancer Med. 2022 Oct;11(19):3623-3632. doi: 10.1002/cam4.4748. Epub 2022 Apr 17.
9
Can Gastric Cancer Patients with High Mandard Score Benefit from Neoadjuvant Chemotherapy?高 Mandard 评分的胃癌患者能从新辅助化疗中获益吗?
Can J Gastroenterol Hepatol. 2022 Mar 25;2022:8178184. doi: 10.1155/2022/8178184. eCollection 2022.
10
Tumor-Infiltrating Lymphocytes as Biomarkers of Treatment Response and Long-Term Survival in Patients with Rectal Cancer: A Systematic Review and Meta-Analysis.肿瘤浸润淋巴细胞作为直肠癌患者治疗反应和长期生存的生物标志物:一项系统评价和荟萃分析
Cancers (Basel). 2022 Jan 27;14(3):636. doi: 10.3390/cancers14030636.